AnalysisHow patent protection impacts drug availability in Russia. An analysis of disputes surrounding Xarelto, Tagrisso, and Ozempic. Compulsory licenses, evergreening patents, and strategies of Russian pharmaceutical companies.
AnalysisAnalysis of Russia's pharmaceutical market in 2024: domestic drugs reached 75-80% share by volume, progress in generic production, and persistent dependence on imported active pharmaceutical ingredients. Prospects for the Pharma 2030 strategy.